The present study was designed to investigate the antidiabetic potential of different extracts of Berberis aristata bark, in alloxan induced diabetic male wister albino rats (150-250g), Diabetes was confirmed after 5 days of single intraperitoneally injection of alloxan (140 mg/kg of body wt.) in 12 hours previously fasted rats. Petroleum ether extract of Berberis aristata (PEBA) (100 & 400 mg/kg, body wt.) & Ethanolic extract of Berberis aristata (EEBA) (100 & 400 mg/kg, body wt.) and the standard drug glibenclamide (10 mg/kg, body wt.) were given orally in 0.5% Tween 80 after 5 days of alloxan treatment daily for 20 days, except the normal and diabetic control group (n=6). Blood was collected from the retro orbital sinus of the rats for glucose, total cholesterol and triglyceride level determination on 1st, 5th, 10th and 20th days. PEBA (100 & 400 mg/kg, body wt.) showed significant reduction in blood glucose level (266.3 ± 0.9700 to 118.1 ± 0.9375mg/dl & 271.3 ± 0.6983 to 111.6 ± 0.8072 mg/dl, respectively), total cholesterol (92.40±0.7711mg/dl & 88.95±0.8144mg/dl, respectively) and triglycerides (78.58±0.9250mg/dl & 69.30±0.8963mg/dl, respectively) and EEBA (100 & 400 mg/kg, body wt.) showed significant reduction in blood glucose level (264 ± 0.7881 to 115.8 ± 0.8931 mg/dl & 278.9 ± 0.6906 to 101.80 ± 0.7490 mg/dl, respectively), total cholesterol (87.80±0.4683 mg/dl and 83.55±0.7680 mg/dl, respectively) and triglycerides (74.47±0.5748 mg/dl & 67.52±0.6833 mg/dl, respectively) that comparable to glibenclamide showed significant reduction in blood glucose level (251.8±0.6009 to 99.17±0.5283 mg/dl), total cholesterol (82.66±0.5845 mg/dl) and triglycerides (62.07±0.5175 mg/dl). It is concluded that PEBA & EEBA (400 mg/kg) possess better antidiabetic potential in alloxan induced diabetic rats.